Clinical Trials at the OHSU ALS and Neuromuscular Disease Center

Clinical trials are the final step in a long process of research. They allow scientists to test the value of their research to diagnose, treat and prevent diseases and disabilities. Each clinical trial is an opportunity to test a promising new invention or treatment in humans for the first time.

For information on current clinical trials for people with ALS and neuromuscular disorders, please contact Diana Dimitrova at dimitrov@ohsu.edu or 503 494-7269.

Status Title

Recruiting

Cross-Sectional ALS Biofluid Biomarker (CABB) Study

Recruiting

Patient Assisted Intervention for Neuropathy: Comparison of Treatment in Real Life Situations (PAIN-CONTRoLS)

Not recruiting yet

A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of ACE-083 in Patients with Facioscapulohumeral Muscular Dystrophy

Not recruiting yet

A phase 3 randomized, multicenter, multinational, double-blinded study comparing the efficacy and safety of repeated biweekly infusions of neoGAA (GZ402666) and alglucosidase alfa in treatment-naïve patients with late-onset Pompe disease

Not recruiting yet

Evaluation of the safety and efficacy of AMX0035, a fixed combination of Phenylbutyrate (PB) and Tauroursodeoxycholic Acid (TUDCA), for treatment of amyotrophic lateral sclerosis (ALS): A double blind placebo controlled Phase II study

Not recruiting yet

Investigating Pompe Prevalence in NEuromuscular Medicine Academic Practices (IPANEMA Study)

Not recruiting yet
Prospective, double-blind, randomized, placebo-controlled phase III study evaluating efficacy and safety of octagam 10% in patients with dermatomyositis (ProDERM study)

Closed to enrolment

A phase III, open-label, extension trial of ECU-MG-301 to evaluate the safety and efficacy of eculizumab in subjects with refractory generalized  Myasthenia Gravis (gMG)

Closed to enrolment

Extension of the CBYM338B2203 phase IIb/III study to evaluate the long-term efficacy, safety and tolerability of intravenous BYM338 in patients with sporadic inclusion body myositis

Closed to enrolment

Phase 2 Study of Rasagiline for Treatment of Amyotrophic Lateral Sclerosis

Closed to enrolment

A Phase 3, Multi-National, Double-Blind, Randomized, Placebo-Controlled, Stratified, Parallel Group, Study to Evaluate the Safety, Tolerability and Efficacy of Tirasemtiv in Patients with Amyotrophic Lateral Sclerosis (ALS)

Completed

A randomized, double-blind, placebo-controlled, multi-center study to evaluate the safety and efficacy of eculizumab in subjects with refractory generalized Myasthenia Gravis (gMG)

Completed

A randomized, double-blind, placebo-controlled, multicenter, parallel group, dose-finding, pivotal, phase IIb/III study to evaluate the efficacy, safety and tolerability of intravenous BYM338 at 52 weeks on physical function, muscle strength, and mobility and additional long-term safety up to 2 years in patients with sporadic inclusion body myositis